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The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed
multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months. The study was
carried out on 234 patients who received THAL for relapsed/refractory myeloma. Out of the 234 patients, 129 patients (55.1%)
responded to THAL with a mean response duration of 11.9 months (ranging from 1 to 48) and an overall survival rate of 20.3
months (ranging 1–55 months). In 64 patients (27.4% of the whole group), the response to THAL lastedX18 months with a mean
response lasting 24 months. Statistical analysis of the group of nonresponders and patients with long-term response to THAL showed
a significantly higher serum albumin level (P¼ 0.0003) and haemoglobin level (P¼ 0.05), as well as a lower b2 microglobulin (b2M)
(P¼ 0.022), LDH (P¼ 0.045) serum level in patients with long-term response. In this study, the LDH and serum albumin level were
predictors for response to THAL therapy. The b2M serum level was not a predictor for response to THAL. The albumin serum level
was the best parameter distinguishing the group of patients with long-term response to THAL from the entire responding group
(P¼ 0.02).
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Multiple myeloma (MM) is a plasma cell malignancy characterised
by the accumulation of long-lasting plasma cells in the bone
marrow and/or extramedullar sites. Conventional chemotherapy
produces an overall response rate of 40–60% with a median
survival of about 3.5 years. Aggressive, high-dose chemotherapy,
bone marrow transplantation and intensive supportive care
allowed for an increase in survival of up to 4–6 years. However,
patients with primary resistant disease and those who relapse after
a response have a median survival duration of 15 and 12 months,
respectively. The disease still remains incurable and almost all
patients eventually relapse and become resistant to cytostatics.
New treatments have recently been developed to overcome drug
resistance, which target the MM cell, the MM cell–host interaction
and the bone marrow (BM) microenvironment. Thalidomide
(THAL) and its immunomodulatory derivatives are examples of
such agents that target the tumour cell in its BM milieu, and which
make possible responses even in refractory or relapsed MM.
THAL, used as a sedative drug in the 1960s, was withdrawn
from clinical use because of its severe teratogenicity but has been
reintroduced because of its immunomodulating and antiangio-
genic properties (Rajkumar and Witzig, 2000). The exact mechan-
ism of THAL action on MM is still unclear. Some postulated effects
of THAL are: the inhibition of proangiogenic cytokines, such
as vascular endothelial growth factor (VEGF), basic fibroblastic
growth factor (bFGF) (Dmoszynska et al, 2000; Kyle and
Rajkumar, 2001) and the downregulation of the secretion
of proinflammatory cytokines such as interleukin-6 (IL-6), tumor
necrosis factor (TNF) (Moreira et al, 1993; Turk et al, 1996);
upregulation of adhesion molecules (Geitz et al, 1996) and the
stimulation of cytotoxic T-cell proliferation and the secretion
of interferon-g and interleukin-2 (Haslett et al, 1998). First reports
concerning the application of THAL in MM were published in
1999 by Singhal et al (1999). Since then, the efficacy of THAL
in refractory or relapsed MM patients was confirmed by
many other authors (Juliusson et al, 2000; Kneller et al, 2000;
Barlogie et al, 2001a,b; Hus et al, 2001; Kumar et al, 2003) with a
response rate ranging from 32 to 64%. However, many questions,
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such as that of the optimal dose, duration of therapy and the
factors predicting response to THAL treatment are still only
partially answered.
The aim of this study was to assess the prognostic value of
pretreatment clinical and laboratory parameters in refractory or
relapsed MM patients with a long-term response to THAL, lasting
at least 18 months.
MATERIALS AND METHODS
Patients
The study group comprised 234 patients (117 women and 117
men) with an average age at 59.6 years (ranging from 19 to 87
years) who received THAL for relapsed or refractory myeloma in
eight Polish centres between March 1999 and October 2003. All
patients signed an informed consent approved by the Local Ethics
Committee and in agreement with STEPS (the System for
Thalidomide Education and Prescribing Safety Programme).
Thalidomide was supplied in 100mg tablets by Gruenenthal
GmbH (Aachen, Germany). The dosage was started at 200mg
daily, and increased as tolerated by 100mg every week to a final
dose of 400mg daily after 3 weeks.
After reports concerning the synergy between THAL and
dexamethasone (Dex) were published, Dex was added to THAL
for newly included patients in a dose of 40mg daily, divided into
two doses for 4 days per month and 78 patients were treated with
this protocol. There was no prior THAL monotherapy in this
group.There were no statistical differences in the clinical and
laboratory parameters among those patients on THAL mono-
therapy and those on the combated treatment.
The treatment was continued until either the disease progressed
or adverse reactions X grade 3 according to WHO occured.
The pretreatment and monthly follow-up evaluation included
a full blood count, renal and liver function tests: the serum
levels of immunoglobulins, b2-microglobulin (b2M),
lactate dehydrogenase, C-reactive protein and Bence–Jones
protein in urine; serum protein electrophoresis and serum and
urine light chains. There was also a monthly neurological
examination.
The response to the treatment was evaluated every 4 weeks in
the first 6–8 months of therapy. The criteria of complete remission
were total disappearance of the serum monoclonal protein and/or
a 90% decrease in the baseline value of the 24-h urinary excretion
of light chain protein as well o 5% plasma cells in the bone
marrow biopsy, normalisation of haemoglobin, albumin and
calcium levels. Partial response was defined as a 50% or greater
reduction in the pretreatment value of the M-protein in serum and
urine and normalisation of serum calcium. Minor response was
defined as a reduction between 25 and 50% of the pretreatment M-
protein value. An increase of the M-protein concentration by 25%
in relation to the lowest value found during the treatment, an
increase in 24-hour urinary Bence–Jones protein excretion to
more than 2.0 g day1 and reappearance of the M-component in
serum or urine were described as progression during the THAL
therapy.
Patients were divided into three groups according to the
response to THAL treatment: patients with no response (group
A), patients with a response lasting between 3 and 18 months
(group B) and patients with a long-term response, X 18 months
(group C). The characteristics of the patient groups are presented
in Table 1.
An analysis of pretreatment parameters distinguishing patients
with a long-term response to THAL (group C) from the other
patient groups (B and C) was performed.
Toxicity and adverse events occurring during THAL therapy
were evaluated according to the WHO grading system. The
occurrence of grade X2 WHO toxicity prompted a THAL dose
reduction, whereas drug administration was to be stopped in case
of X3 WHO toxicity.
Table 1 Patient characteristics before thalidomide (THAL) treatment: group A–nonresponders’ group. Group B–patients with response for THAL
treatment 43 months and o 18 months, group C–patients with response for THAL treatment X18 months
Age median/
range (years) Sex
Stage according
to Durie –Salmon
Type of
paraprotein
Number of
chemotherapy
cycles before
TAHL median/
range
Number of
chemotherapy
lines before TAHL
median/range
Group A 61 F-49 I-5 IgG-68 10 3
(19–87) M-56 II-18 IgA-24 (3–49) (1 – 5)
III-81 LCD-10
Solitare-1 IgD-2
NS-1
Group B 60 F-34 I-3 IgG-47 10 3
(35–79) M-31 II-14 IgA-17 (3–40) (1 – 6)
III-48 LCD-1
Group C 63 F-37 I – 2 IgG-46 13 3
(32–79) M-27 II – 22 IgA-12 (4–63) (1 – 6)
III-40 LCD-6
B2 M (mg l1)
median/range
CRP (mgdl1)
median/range
LDH (U l1)
median/range
WBC (G l1)
median/range
HB (g dl1)
median/range
PLT (G l1)
median/range
Plasma cells in BM
on biopsy (%)
median/range
Serum albumins
(g dl1)median/
range
Group A 4.04 3.9 351 4.55 10.4 170 24 3.8
(1.08 –31.0) (0.0 –65.0) (94.0 –1500.0) (1.8 –18.5) (5.0 –15.9) (11 –506) (3.0 – 83.0) (1.9 –5.3)
Group B 3.69 3.82 304 4.2 10.84 187 21 3.9
(1.18 –10.97) (0.0 –25.0) (51.0 –652.0) (0.4 –9.5) (6.7 –14.4) (1.0 –488.0) (3.0 – 70.0) (2.8 –4.7)
Group C 3.2 3.72 293 3.85 11 183 24 4.1
(1.4 –17.7) (0.0 –19.3) (46 –923.0) (1.8 –13.0) (7.5 –14.6) (27.0 –817.0) (1.0 – 90) (2.96 –4.85)
LCD¼ light chain disease; NS¼ nonsecretory.
Long-term response to THAL in MM patients
I Hus et al
1874
British Journal of Cancer (2004) 91(11), 1873 – 1879 & 2004 Cancer Research UK
C
lin
ic
a
l
Statistical analysis
The statistical significance of the differences observed between the
three patient groups was determined by using the U Mann–
Whitney and Spearman test. The effect was considered as
statistically significant if the P-value of its corresponding test
statistic was p0.05.
RESULTS
Out of 234 patients, 129 patients (55.1%) responded to THAL
treatment with a mean response duration of 11.9 months (ranging
from 1 to 48) and an overall survival rate of 20.3 months (range 1–
55). In 64 patients (27.4% of the whole group), the response to
THAL lastedX18 months (group C) with a mean response lasting
24 months. In 105 patients (44.9%), there was no response (group
A), while in 65 patients, the response lasted more than 3 months
but less than 18 months (group B). The overall survival (OS) and
event-free survival (EFS) rate in group A was 13.6 months (ranging
from 1 to 38) and 4.2 months (1–15), respectively. Overall survival
and EFS in group B was 22.7 months (range 7–54) and 11.37
months (3–24), respectively. The OS and EFS in group C was 29.1
months (ranging from 18 to 55) and 24 months ranging from (18–
48). Differences in the OS and EFS were statistically significant
(Figures 1 and 2).
In the entire patient group, the response rate to the combined
treatment was slightly higher in patients receiving the THALþDex
treatment than in patients on THAL monotherapy (59.3 vs 55.1%).
However, the number of patients on the combined treatment or on
THAL alone was similar in all three patient groups.
None of the estimated clinical parameters seemed to influence
the duration of response to THAL therapy. The distribution of sex,
the number of chemotherapy lines and cycles, number of
refractory and relapsed patients, as well as the number of patients
with prior autologous peripheral blood stem cell auto (autoPBSCT)
was similar in the three groups of patients (Table 1).
Comparing the pretreatment laboratory parameters in patients
responding to THAL and those not responding, statistically
significant differences were found in the albumin serum levels
(P¼ 0.002) (Figure 3), LDH (P¼ 0.025) (Figure 4) and the WBC
count (P¼ 0.049).
Statistical analysis of patients from groups A and C showed
significantly higher serum levels of albumin (P¼ 0.0003) and
haemoglobin (P¼ 0.05), as well as a lower level of b2M (P¼ 0.022);
and a decreased LDH serum activity (P¼ 0.045) and WBC count
(P¼ 0.044) in group C (Table 1).
The only one significant difference between patient groups
responding to THAL longer (group C) or shorter than 18 months
(group B) was the higher pretreatment serum albumin level in
group C (P¼ 0.024) (Table 1).
An analysis of clinical and laboratory parameters and of the
survival of patients in group C showed a statistically significant,
negative correlation between the LDH serum level and the OS
(Figure 5).
The serum albumin concentration was the only one parameter
predicting a long-term response to THAL therapy. Moreover, a
multivariate analysis showed that both the OS and EFS in the entire
group of MM patients were influenced by a serum albumin level
o35g l1 (Tukey’s test, P¼ 0.009; P¼ 0.003; respectively). In
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Figure 1 Event-free survival in patients group A, B and C (Test F Cox’a:
P¼ 0.00028 between group A and B; P¼ 0.00005 between A and C;
P¼ 0.042 between B and C).
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Figure 2 Overall survival in patients group A, B and C (Test F Cox’a:
P¼ 0.00032 between group A and B; P¼ 0.00002 between A and C;
P¼ 0.022 between B and C).
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Figure 3 Albumin serum level in patients nonresponding (group A) and
responding (group BþC) to THAL treatment (P¼ 0.002).
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patients with a serum albumin level o 35g l1 the mean EFS and
OS were, respectively, 8.2710.4 and 12.1711.3 months. In patients
with a serum albumin level435 g l1, the mean EFS and OS were,
respectively, 14.8þ 10.4 and 17.679.4 months (Figures 6 and 7).
The adverse events connected with THAL therapy are listed in
Table 2. Constipation, somnolence and fatigue were observed in
three-quarters of patients during THAL treatment. There were no
significant differences between the frequency of the occurrence of
adverse events in groups B and C. Seven patients (group B),
developed polineuropathy (grade 3 according to WHO) resulting
in the withdrawal of THAL treatment. Other adverse reactions
causing the discontinuation of THAL therapy in single patients
were: Deep vein thrombosis (DVT), cardiac arrhythmia, skin rash
and cerebrovascular ischaemia. One patient died from myocardial
infarction.
DISCUSSION
Thalidomide, a glutamic acid derivative with antiangiogenic,
immunomodulatory and proapoptotic properties, has been re-
cently introduced as a salvage therapy for relapsed or refractory
myeloma patients. It has been demonstrated to be highly effective
as a single agent, not only in patients resistant to conventional
chemotherapy but also in those relapsing after intensive che-
motherapy with autologous stem cell transplantation, high-dose
steroids or those who had been heavily pretreated (Juliusson et al,
2000). The results obtained in 234 patients, one of the largest
reported groups of resistant or relapsed MM patients treated with
THAL, as well as the results reported by several other authors, are
presented in Table 3.
The objective of our study was to identify the prognostic factors
for long-term response (longer than 18 months), and the EFS and
OS among clinical and laboratory parameters estimated before the
start of THAL therapy.
b2M is a well-established prognostic factor in MM patients.
A high serum b2M is a predictor of poor survival in patients
treated with conventional chemotherapy (Rajkumar and Greipp,
1999). There is excellent correlation between serum b2M levels
and myeloma tumour burden. It was shown that b2M was
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Figure 4 LDH serum activity in patients nonresponding (group A) and
responding (group BþC) to THAL treatment (P¼ 0.025).
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Figure 5 Correlation between LDH serum level and OS in patients with
response to THAL lasting 418 months (group C) (P¼ 0.0013).
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an independent predictor of both OS and EFS after transplantation
for MM.
A statistical analysis of this study showed the lowest b2M serum
level in patients with a response to THAL lasting more than 18
months, and the highest level in the nonresponders’ group. This
difference was statistically significant. The b2M serum level in
patients with a response to THAL lasting between 3 and 18 months
was higher than in patients with a long-term response, but this
difference was not significant. So, in this study b2M was not a
predictor of long-term response.
Another important laboratory parameter identified as a poor
prognostic factor in MM patients is lactate dehydrogenase (LDH)
serum activity. Elevated LDH concentration has been associated
with an aggressive MM phenotype (Fonseca et al, 2001) and
patients with a high LDH level have a shorter survival rate. We
found that the LDH serum level was significantly higher in the
nonresponding patients than in the responding ones. However, the
mean level was similar in responding patients (group B and C)
independent of the duration of response. The analysis of survival
also showed a significant negative correlation between the OS and
the LDH serum level in patients with a long response to THAL.
Of the parameters used in the Durie–Salmon staging system,
only haemoglobin concentration was significantly higher in
patients with a long-term response as compared to the non-
responding patients. In the nonresponders’ group, low haemoglo-
bin concentration correlates with the highest percentage of
patients with the III clinical stage according to Durie–Salmon,
as compared to the group of patients with a long-term response to
THAL (77.5 vs 63%).
The albumin serum level, although not incorporated into the
Durie–Salmon staging system, is also considered to be an
important prognostic factor in MM. The albumin serum level
was the highest in patients with a long-term response compared to
the other groups, and the differences were statistically significant.
In this study, the serum albumin level was the only one parameter
distinguishing the group of patients with a long-term response to
THAL treatment from the whole responding group (P¼ 0.02).
Moreover, in a multivariate analysis, a serum albumin level o
35 g dl1 influenced the EFS and OS in the entire patient group.
An especially interesting case among our MM patients treated
with THAL was the patient with an extremly long-term response to
THAL therapy, achieved despite unfavourable prognostic factors at
presentation, such as high serum b2M level, -13q deletion and
MDR-1 gene expression. The patient did not respond to primary
chemotherapy. It should be stressed that his serum albumin level
was normal and the patient was succesfully treated with THAL for
36 months. Now, 14 months after THAL cessation, he is still in
complete remission receiving no specific treatment. Moreover in
this patient, THAL treatment resulted in the overcoming of the
MDR (multidrug resistance) phenomenon.
The evaluation of baseline prognostic parameters predicting the
response to THAL treatment, and the OS and EFS in refractory and
relapsed MM patients was performed in previous studies by other
authors. However, the patient groups were much less numerous
and the observation period shorter.
In the first reported trial of THAL in patients with refractory
myeloma, Singhal et al (1999) reported increased LDH levels,
plasma-cell-labelling index (PCLI) and CRP levels as the predictors
of a brief period of EFS, whereas low albumin levels, deletion of
chromosome 13 and high numbers of plasma cells in BM were
associated with relatively short OS. Barlogie et al (2001a,b) found
elevated CRP (47mg l1), b2M levels (43mg l1), high PCLI
(40.5%) and abnormal cytogenetics (deletion 13) to be a
unfavourable prognostic factors for initial response to THAL and
for EFS and OS in 169 MM patients treated with THAL.
Yakoub-Agha et al (2002) reported that pre-THAL features
associated with a poor chance of OS and EFS included an IgA
isotype, a platelet counto80G/L and a serum albumin levelo3 g l1.
In the prospective study of advanced MM treated with THAL,
Grosbois et al (2003) found that the best factors for a good response
were the status at inclusion (refractory or relapsed), a b2M level and
platelet count. A multivariate analysis of the OS of relapsed or
refractory MM patients demonstrated that advanced age (exceeding
65 years) raised the serum level of LDH and also the concentration of
creatinine predicted inferior outcomes (Mileshkin et al, 2003).
Table 2 Adverse events during Thal treatment: group B: patients
responding to Thal o18 months, group C: patients responding to Thal
X18 months
Toxicity according to WHO
Grade 1–2 (%) Grade 3–4 (%)
Adverse reaction Group C Group B Group C Group B
Constipation 73.0 78.2 — 1.7
Fatigue 75.7 62.7 — —
Somnolence 78.4 66.1 — —
Skin rash 5.4 4 — 0.8 (1pt)
Neurological toxicity
polyneuropathy 59.5 55 — 5.9
CNS cerebrovascular ischaemia — — 2.7 (1pt) 1.7 (2pts)
vertigo — 2.5 (2 pts) — —
Deep vein thrombosis — — 2.7 (1 pt) 1.7 (2pts)
Cardiovascular toxicity
Arrhythmia 13.5 10.2 — —
Cardiac infarction — — 2.7 (1pt) —
Chronic heart failure — 1.5 (1 pt) — 4.6
Leucopoenia 22.9 24.5 8.3 3.8
Pt¼ Patient.
Table 3 Thalidomide therapy in relapsed / refractory multiple myeloma
Number of pts Thal dose (mgd1) Follow-up period (months) Response rate (%) Comments
84 200–800 14.5 32 12-months OS 58% Singhal et al (1999)
12-months EFS 22%
169 200–800 30 36 24-months OS 48% Barlogie et al (2001)
24-months EFS 20%
83 50–800 18 66 18-months OS 40% Yakoub-Agha et al (2002)
18-months EFS 30%
121 200–400 24 31.4 24-months OS 30% Grosbois et al (2003)
24-months EFS 15%
75 200–800 26 28 18-months OS 48% Mileshkin et al (2003)
24-months PFS 18%
191 200–400 39 56 Dmoszynska et al (2003)
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Since an antiangiogenic effect is postulated as one of the most
important mechanisms of THAL action pretreatment, angiogenesis
was evaluated as a predictor of response. Cheng et al (1999) found
that a high pretreatment microvessel density (MVD) predicted a poor
response to THAL therapy, but this needs confirmation in a larger
study. Neben et al (2001) reported that high plasma bFGF
concentration is associated with a better response to THAL in
progressive MM. Dmoszynska et al (2001, 2002) found that the major
response to THAL was observed in patients with the highest VEGF
pretreatment level compared to patients with a minor response.
As for now, there are no generally approved factors predicting
the response to THAL in MM patients. The most often postulated
ones are PCLI, abnormal cytogenetics, b2M and CRP. Since PCLI
and cytogenetics are usually not available in the standard practice
setting outside of specialised centres, b2M and CRP have an
independent prognostic importance for survival. The results of our
study confirm the results obtained by Singhal et al (1999) and
Yakoub-Agha et al (2002) that the albumin serum level is a useful
parameter, determining the response to THAL treatment.
In previous studies, the synergistic effect of THAL and Dex, as
well as the prevalence of the combined treatment over mono-
therapy was shown (Cavenagh and Oakervee, 2003). The response
rate to THALþDex in previously treated MM patients was up to
48% (Cavenagh and Oakervee, 2003; Anagnostopoulos et al, 2003).
A higher response rate (64%) was observed only in newly
diagnosed or untreated patients (Rajkumar et al, 2002). Weber
et al (1999) achieved a response for THALþDex in 35% of
patients previously resistant to THAL or Dex alone. In our study,
the combined treatment of THALþDex had an increased response
rate of 59.3% compared to THAL alone (55.1%). Although the
number of patients on the combinated treatment or on THAL
alone was similar in all the groups, the addition of Dex did not
influence the duration of the response.
Several authors postulated a dependence between a cumulative
dose of THAL administrated during the first 3 months of treatment
and the clinical outcome. Barlogie et al (2001a,b) evaluating
patients treated with doses from 200 to 800mg daily demonstrated
that patients receiving a cumulative dose of more than 42 g of
THAL in 3 had a higher rate of response (54 vs 21%) and a 2-year
survival rate (63 vs 45%).
Neben et al (2002) noted that after 18 months of THAL treatment,
patients tolerating the maximum THAL dose of 400mg daily (a
cumulative 3-month THAL dose of 31.8 g) had a predicted PFS and
OS 15–20% higher when compared with patients with a dose of
200–400mg (a cumulative 3-month THAL dose of 19.8 g). Other
data show that responses lasting 15 months could be achieved with
doses as low as 50mg daily (Lee, 2002; Leleu et al, 2002).
In this study, in 3 months from the start of therapy, 85% of
patients reached the dose of 400mg daily (a cumulative dose of
34.4 g). This medium dose of THAL was effective in 129 patients
(55.1%), and in 64 patients (29%) a long-term response was
obtained lasting more than 18 months. It would be reasonable to
reduce the drug dose to the lowest level that would still be effective.
Unfortunately, the question of the minimal effective THAL dosage
is still unresolved.
Although higher doses of THAL may be associated with a higher
response rate, they may also be associated with a higher incidence
of side effects and the discontinuation of therapy.
In doses of up to 400mg daily, THAL is generally well tolerated.
The most common side effects of the therapy are sedation, fatigue
and constipation. They are generally mild and in these doses rarely
lead to the discontinuation of treatment. A major potential adverse
reaction connected with THAL is peripheral neuropathy, which
can be irreversible. This generally occurs following a chronic use of
THAL over a period of a month although reports regarding a
relatively short-term use also exist. The correlation with the
cumulative dose is unclear.
In this study, the incidence of polineuropathy was similar in
groups of patients responding to THAL longer (group C) or
shorter than 18 months (group B). In the majority of cases, it
revealed itself within 12 months of therapy.
Neuropathy grade 3 according to WHO causing the disconti-
nuation of therapy was observed in seven patients during the first
12 months of THAL treatment. Other serious side effects that may
occur during THAL therapy are deep vein thrombosis (DVT) and
CNS vascular ischaemia. The frequency of DVT and CNS vascular
ischaemia was similar before (two patients, two patients,
respectively) and after (one patient, two patients, respectively) 18
months of THAL therapy, respectively. Generally, long-term THAL
therapy was safe and well tolerated.
The conclusion based on our results is that THAL as a single
agent is effective in refractory and relapsed MM patients and that
of various established MM prognostic factors, the pretreatment
serum albumin level identified the group of patients with a long-
term response to THAL therapy.
Taking into account the above conclusion, in the case of
patients with a low pretreatment serum albumin level a
decision concerning SCT should be considered immediately after
achieving a response to THAL. It has been confirmed by
many study groups that THAL as a single agent (Dmoszynska
et al, 2000; Patriarca et al, 2003) or combined with VAD
(Ahmad et al, 2002; Pitini et al, 2003) could be a suitable
bridging regimen to PBSC collection and autologous SCT
for VAD-refractory MM patients. Moreover, Ghobrial et al
(2003) showed that THAL does not substantionally affect
peripheral blood mobilisation or engraftment, which is in line
with our observation.
For patients with low pretreatment level, other therapeutical
options, such as a combination of THAL with chemotherapy or
bortezomid, should be considered since such options can
significantly increase the response rate. Total response rate to
THAL combined with cyclophosphamide and Dex was 83 %
(Garcia-Sanz et al, 2004). Other succesful combined regimens are
T-VADdoxil (74%) (Zervas et al, 2004), THAL–melphalan (80%)
(Offidani et al, 2003).
The majority of patients in our study responded to a medium
dose of 400mg. The long-term response rate was 50% of all
patients responding to THAL therapy, and it was well tolerated by
the majority of patients even in long-term therapy.
The efficiency of THAL and other new immunomodulatory
drugs have opened up a new era in MM therapy. There is no doubt
that THAL is the most active single agent used in relapsed or
refractory MM patients in the last decade. In summarising this
long-term observation, we can conclude that THAL is a relatively
safe drug, which can be administered over a long period of time,
offering many patients a longer life.
REFERENCES
Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexamnn R (2003)
Thalidomide and dexamethasone for resistant multiple myeloma. Br J
Haematolo 121: 768–771
Ahmad I, Islam T, Chanan -Khan A, Hahn T, Wentling D, Becker JL,
McCarthy Jr PL, Alam AR (2002) Thalidomide as salvage therapy for
VAD-refractory multiple myeloma prior to autologousPBSCT. Bone
Marrow Transplant 27: 577–580
Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros
A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D,
Tricot G (2001a) Extended survival in advanced andrefractory multiple
Long-term response to THAL in MM patients
I Hus et al
1878
British Journal of Cancer (2004) 91(11), 1873 – 1879 & 2004 Cancer Research UK
C
lin
ic
a
l
myeloma after single-agent thalidomide: identification of prognostic
factors in aphase 2 study of 169 patients. Blood 98: 492–494
Barlogie B, Tricot G, Anaissie E (2001b) Thalidomide in the management of
multiple myeloma. Semin Oncol 28: 577–582
Cavenagh JD, Oakervee H (2003) Thalidomide in multiple myeloma-
current status and future prospects. Br J Haematol 120: 18–26
Cheng D, Kini AR, Rodriguez J, Burt R, Peterson LC, Tray nor AE (1999)
Microvascular density and cytotoxic T cell activation correlate with
response to thalidomide therapy in myeloma patients. Blood 94(Suppl 1):
315a
Dmoszynska A, Bojarska-Junak A, Domanski D, Rolnski J, Hus M, Soroka-
Wojtaszko M (2002) Production of proangiogenic cytokines during
thalidomide treatment of multiple myeloma. Leuk Lymph 43: 401–406
Dmoszynska A, Hus M, Legiec W, Walter-Croneck A, Wach M (2000)
Delayed stem celltransplantation in patients with relapsed or refractory
multiple myeloma using lhalidomide as a preparative regimen. Blood
96(Suppl 1): 5345
Dmoszynska A, Hus M, Soroka-Wojtaszko M, Mariko J, Jawniak D, Legiec
VV, Grzasko N, Hellmann A, Ciepluch H, Baran W, Skotnicki A, Wolska-
Smolen T, Sutek K, Borysewicz-Czajka T, Sawicki W, Robak T,
Szmigielska A, Konopka L, Pszenna E, Szpila T, Kloczko J, Piszcz J,
Zdziarska B (2003) Multicenter clinical study of thalidomide efficacv in
patients with refractory and relapsed multiple myeloma. Hematology J
4(Suppl 1): 226
Fonseca R, Conte G, Greipp PR (2001) Laboratory correlates in multiple
mveloma: how useful for prognosis? Blood Rex 15: 97–102
Garcia-Sanz R, Gonzalez-Poraz JR, Hernandez JM, Polo-Zarzuela M,
Surreda A, Barrenetxea C, Palomera L, Lopez R, Grande-Garcia C,
Alegre A, Vargas-Pabon M, Gutierez ON, Rodrigez JA, San Miguel JF
(2004) The oral combination of thalidomide, cyclophosphamide and
dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple
myeloma. Leukemia 18: 856–863
Geitz H, Handt S, Zvvingenberger K (1996) Thalidomide selectively
modulates th density of cell surface molecules involved in the adhesion
cascade. Immunopharmacology 31: 213–221
Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV,
Therneau TM, Lacv MQ, Witzig TE, Litzow MR, Christensen BR,
Hayman S, Pribula CG, Gertz MA (2003) Effect of thalidomide on stem
call collection and engraftment in patients with multiple myeloma. Bone
Marrow Transplant 32: 587–592
Grosbois B, Belissant P, Moreau P, Attal M, Voillat L, Muret P, Pegourie B,
Tiab M, Berthou C, Duguet C (2003) Treatment of advanced multiple
mveloma (MM) with thalidomide (THAL). Long term folow-up in a
prospective study of 121 patients. Hematulogy 4(Suppl 1): 226
Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide
costimulates primary human T lymphocytes, preferentially inducing
proliferation, cytokine production and cytotoxic responses in the CD8+
subset. J Exp Med 187: 1885–1892
Hus M, Dmoszyriska A, Soroka-Wojtaszko M, Jawniak D, Legiec W,
Ciepluch H, Hellmann A, Wolska-Smoleh T, Skotnicki A, Manko J (2001)
Thalidomide treatment of resistant or relapsed multiple mveloma
patients. Hematologica 86: 404–408
Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000)
Frequent good partial remissions from thalidomide including best
response ever in patients with advanced refractor), and relapsed
myeloma. Br J Haemalol 109: 89–96
Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicv M, Ben-Bassat
I (2000) Therapv with thalidomide in refractor) multiple myeloma
patients– the revival of an old drug. Br J Haematol 108: 391–393
Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL,
Fonesca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE,
Rajkumar SV (2003) Response rate, durability of response, and survival
after thalidomide therapy for relapsed multiple mveloma.Mayo Clin Proc
78: 34–39
Kyle RA, Rajkumar V (2001) Therapeutic application of thalidomide in
multiple myeloma. Semin Oncol 28: 583–587
Lee FC (2002) Second response to lower-dose thalidomide in a patient with
multiple mveloma. Blood 99: 4248
Leleu X, Magro L, Fawaz A, Banters F, Facon T, Yacoub-Agha I (2002)
Efficacy of a low dose of thalidomide in advanced multiple myeloma.
Blood 100: 1519–1520
Mileshkin L, Biagi JJ, Mitchel P, Underhill C, Grigg A, Bell R, McKendrick J,
Briggs P, Seymour JF, Lillie K, Smith JG, Zeldis JB, Prince HM (2003)
Multicenter phase 2 trail of thalidomide in relapsed refractory multiple
myeloma: adverse prognostic impact of advanced age. Blood 102: 69–77
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smidt KA, Kaplan G
(1993) Thalidomide exerts its ihibitory action on tumor necrosis factor
alpha by enhancing mRNA degradation. J Exp Med 177: 1675–1680
Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Mo AD,
Goldschmidt H (2001) High plasma basic fibroblast growth factor
concentration is a^ociaied with response to ihalidomide in progressive
multiple myeloma. Clin Cancer Res 7: 2675–2681
Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt
H (2002) Dose- dependent effect of thalidomide on overall survival in
relapsed multiple mveloma. Clin Cancer Res 8: 3377–3382
Offidani M, Marconi M, Corvatta L, Olivieri A, Catarini VI, Leoni (2003)
Thalidomide plus oral melphalan for advanced multiple myeloma: a
phase II study. Haematologica 88: 1432–1433
Patriarca F, Sperotto A, Prosdocimo S, Geromin A, Zaja F, Fanin R (2003)
Thalidomide before autologous stem cell transplantation in VAD-
refractorv multiple mveloma patients. Huematologica 88: 597–599
Pitini V, Arrigo C, Aloi G, Micali C, La Gattuta G (2003) I halidomide as a
salvage therapv for VAD-refractorv multiple myeloma prior to
autologous PBSCT. Marrow Transplant 31: 1065
Rajkumar SV, Greipp PR (1999) Prognostic factors in multiple myeloma.
Hematol Oncol Clin N Am 13: 1295–1314
Rajkumar VS, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR,
Geyer S, Iturria N, Fonseca R, Lust JA, Kyle R, Witzig TE (2002)
Combination therapy with thalidomide plus dexamethasone for newly
diagnosed myeloma. J Clin Oncol 20: 4319–4323
Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangio-
genic therapy with thalidomide in multiple myeloma. Cancer Treat Rev
26: 351–362
Singhal S, Mehta J, Desikan R, Roberson P, Eddelmon P, Munshi N,
Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999)
Antitumor acmity of thalidomide in refractory multiple myeloma. N Engl
J Med 341: 1565–1571
Turk BO, Jiang H, I.iu JO (1996) Binding of thalidomide to alpha I-acid
glycoprotein may be involved in its inhibition of tumor necrosis factor
alpha production. Proc Natl Acad Sci USA 93: 7552–7556
Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R (1999)
Thalidomide alone or with dexamethasone for multiple myeloma. Blood
94: 604a
Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C,
Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M,
Harousseau JL, Daguet C, Duhamel A, Facon T (2002) Thalidomide in
patients with advanced multiple myeloma: a study of 83 patients-report
of the intergroupe francophone du myelome (IFM). Hematology 7:
3:185–3:192
Zervas K, Dimopoulos A, Hatzicharissi E, Agruistopoulous A, Papaioannau
M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A
(2004) Primary treatment of multiple myeloma with thalidomide,
vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil):
a phase II multicenter studv. Ann Oncol 15: 134–138
Long-term response to THAL in MM patients
I Hus et al
1879
British Journal of Cancer (2004) 91(11), 1873 – 1879& 2004 Cancer Research UK
C
li
n
ic
a
l
